Business Wire

iBASIS Acquires Global Voice, IPX and Messaging Wholesale Assets From Telstra International and Signs Long-Term Agreement for the Provision of These Services

3.9.2025 09:00:00 CEST | Business Wire | Press Release

Share

iBASIS, a leading provider of communications solutions for operators and digital players worldwide, today announced it has signed an Asset Sale and Purchase Agreement (APA) with Telstra to acquire Telstra International’s wholesale voice, mobile, and messaging customer contracts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903751955/en/

From left to right: Roary Stasko, CEO, Telstra International; Patrick George, CEO, iBASIS

The transaction, which is subject to regulatory approvals, represents a major expansion of iBASIS’ commercial scale, geographic reach, and customer portfolio across the Asia-Pacific region, reinforcing its presence in Hong Kong and Singapore, and establishing its presence in Australia and New Zealand. Additionally, iBASIS will obtain exclusive rights for international wholesale voice services for Digicel Pacific, part of the Telstra International portfolio, covering Papua New Guinea, Fiji, Samoa, Tonga, Vanuatu, and Nauru.

The transaction further underpins iBASIS’ positioning as the partner of choice to Tier One domestic carriers for international wholesale services and consolidator of the international wholesale market.

“This long-term partnership with iBASIS offers a strategic opportunity to strengthen our ability to compete globally, while ensuring continuity and quality for our international voice customers. We have full confidence in iBASIS to deliver seamless continuity for our wholesale and retail customers, backed by their proven track record in service delivery and global expertise,” said Roary Stasko, CEO of Telstra International.

“We are extremely proud to partner with Telstra. This marks a significant milestone in iBASIS’ ongoing consolidation strategy,” said Patrick George, CEO of iBASIS. “This transaction accelerates our growth trajectory and strengthens our unique leadership position as a global wholesale player. It validates the relevance of our model as an independent specialist in global wholesale communications, built on high-performing voice and mobile platforms, and expands our reach and presence in the APAC region.”

The transaction involves the transfer of high-value customer contracts and an international team of seasoned commercial and operational professionals. iBASIS is committed to ensuring a seamless transition with uninterrupted service quality for all customers. Existing customer relationships will remain intact and fully supported throughout the integration process.

The transaction is subject to regulatory approval and is anticipated to close before year-end 2025. Dohan Advisory served as the financial advisor to iBASIS in relation to the transaction.

About iBASIS
iBASISis the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high returns on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT.

About Telstra International
Telstra International is a trusted digital infrastructure and connectivity partner in Asia Pacific and the global arm of Telstra, a leading telecommunications and technology company with a proudly Australian heritage. Telstra International provides secure and resilient connectivity solutions to meet the growing needs of thousands of technology, enterprise, and wholesale customers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250903751955/en/

Contacts

Media Contact
Jason McGee-Abe
26FIVE Global Lab
iBASIS@26FIVE.com
+44 7970 237682

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye